Requirements for baculoviruses for clinical gene therapy applications

Lesch, Hanna P.; Makkonen, Kaisa-Emilia; Laitinen, Anna; Määttä, Ann-Marie; Närvänen, Outi; Airenne, Kari J.; Ylä‐Herttuala, Seppo

doi:10.1016/j.jip.2011.05.010

Cited by 17 publications

(14 citation statements)

References 74 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…So far, baculoviruses have long been considered as a biologically safe gene delivery vector for mammalian cells27. Although it has been shown to effectively transduce mammalian cells in vitro , its full potential for in vivo gene therapy is not yet proven.…”

Section: Discussionmentioning

confidence: 99%

“…The viral surface has been chemically modified to form cationic nanostructures, similar to our earlier studies232425, for local delivery of human vascular endothelial growth factor-A 165 (Vegf) therapeutic genes to attenuate ISR26. Insect cell host-specific baculovirus (Bac) offers a unique advantage over other gene delivery systems because of its ability to efficiently transduce non-dividing cells, inherent inability to replicate in mammalian cells, low cytotoxicity even at high viral dosage, absence of preexisting antibodies against Bac in animals and also easy production scale up to high viral titre2728. On the contrary, the widely experimented mammalian viruses have shown high risks of invoking inflammatory responses and probability for random integration into the host mammalian genome leading to inadequate clinical safety profile29.…”

mentioning

confidence: 99%

See 1 more Smart Citation

Bioactive baculovirus nanohybrids for stent based rapid vascular re-endothelialization

Paul

Elias

Shum‐Tim

et al. 2013

Sci Rep

View full text Add to dashboard Cite

Present study, for the first time, reports the development of a nanohybridized baculovirus based stent that can locally promote vascular re-endothelialization by efficient delivery of pro-angiogenic vascular endothelial growth factor (Vegf) genes. In vitro data demonstrated rapid expression of functionally active Vegf by the bioactive stent-transduced vascular cells. In vivo site-specific transgene expression was observed at the stented regions of balloon-denuded canine femoral artery, which eventually lead to significant endothelial recovery at the injured sites. A significant reduction in neointima formation (2.23 ± 0.56 mm2 vs 2.78 ± 0.49 mm2 and 3.11 ± 0.23 mm2, p < 0.05; n = 8) and percent stenosis was observed in treated stent group compared to negative control and bare metal stent groups. These findings collectively implicate the potential of this newly developed baculovirus based biotherapeutic stent to ameliorate damaged vascular biology and attenuate re-narrowing of stented artery by inhibiting neointima formation.

show abstract

Section: Discussionmentioning

confidence: 99%

mentioning

confidence: 99%

Bioactive baculovirus nanohybrids for stent based rapid vascular re-endothelialization

Paul

Elias

Shum‐Tim

et al. 2013

Sci Rep

View full text Add to dashboard Cite

show abstract

“…The baculovirus-expression system is also a promising system to produce viral vectors for gene therapy, mainly adeno-associate virus (AAV) vectors, using a co-infection of three baculovirus vectors (Urabe et al, 2002) and lentiviral vectors (Lesch et al, 2008). See also Galibert andLesch et al (2011).…”

Section: Principle Of the Baculovirus Expression Systemmentioning

confidence: 99%

Opportunities and challenges for the baculovirus expression system

Oers

2011

Journal of Invertebrate Pathology

132

View full text Add to dashboard Cite

“…This unexpected competence for non-host-cell transduction has prompted researchers to design AcMNPV-based vectors for a variety of novel applications including assay development in drug discovery (Kost et al , 2010), RNA interference (Nicholson et al , 2005; Ong et al , 2005), cancer (Wang & Balasundaram, 2010), gene therapy (Ghosh et al , 2002) and engineering of stem cells in tissue regeneration (Lin et al , 2010). A possible regulatory route towards the eventual clinical application of AcMNPV-based vectors has been discussed recently (Lesch et al , 2011). …”

Section: Introductionmentioning

confidence: 99%

Seamless replacement of Autographa californica multiple nucleopolyhedrovirus gp64 with each of five novel type II alphabaculovirus fusion sequences generates pseudotyped virus that fails to transduce mammalian cells

Westenberg

Soedling

Hirani

et al. 2012

Journal of General Virology

View full text Add to dashboard Cite

Autographa californica multiple nucleopolyhedrovirus (AcMNPV), a member of the type I alphabaculoviruses, is able to transduce and deliver a functional gene to a range of non-host cells, including many mammalian lines and primary cells, a property mediated by the envelope fusion protein GP64. AcMNPV is non-cytopathic and inherently replication deficient in non-host cells. As such, AcMNPV represents a possible new class of gene therapy vector with potential future clinical utility. Whilst not a problem for in vitro gene delivery, the broad tropism displayed for non-host cells is less desirable in a gene therapy vector. The fusion protein F of type II alphabaculoviruses can substitute functionally for GP64, and such pseudotyped viruses display a severely impaired capacity for non-host-cell transduction. Thus, surface decoration of such an F-pseudotyped AcMNPV with cell-binding ligands may restore transduction competence and generate vectors with desirable cell-targeting characteristics. By seamlessly swapping the native gp64 coding sequence with each of five sequences encoding different F proteins, a set of F-pseudotyped AcMNPV was generated. This report details their relative abilities both to functionally replace GP64 in viral growth and to transduce human Saos-2 and HeLa cells. All five supported viable infections in insect cell cultures and one, the Mamestra configurata NPV (MacoNPV) F pseudotype, could be amplified to titres close to those of native AcMNPV. In contrast, none was able to transduce the Saos-2 and HeLa cell lines. The robust support provided by MacoNPV F in virus production makes the corresponding pseudotype a viable scaffold to display surface ligands to direct selective mammalian cell targeting.

show abstract

Requirements for baculoviruses for clinical gene therapy applications

Cited by 17 publications

References 74 publications

Bioactive baculovirus nanohybrids for stent based rapid vascular re-endothelialization

Bioactive baculovirus nanohybrids for stent based rapid vascular re-endothelialization

Opportunities and challenges for the baculovirus expression system

Seamless replacement of Autographa californica multiple nucleopolyhedrovirus gp64 with each of five novel type II alphabaculovirus fusion sequences generates pseudotyped virus that fails to transduce mammalian cells

Contact Info

Product

Resources

About